{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:08:45Z","timestamp":1794262125610,"version":"4.9.0"},"reference-count":167,"publisher":"Bentham Science Publishers Ltd.","issue":"3","funder":[{"DOI":"10.13039\/501100004001","name":"Department of Science and Technology of Guizhou Province","doi-asserted-by":"publisher","award":["QKHPTRC [2016]5613\/5677"],"award-info":[{"award-number":["QKHPTRC [2016]5613\/5677"]}],"id":[{"id":"10.13039\/501100004001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009619","name":"Guiyang Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["[2017]30-18\/30-38"],"award-info":[{"award-number":["[2017]30-18\/30-38"]}],"id":[{"id":"10.13039\/501100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005329","name":"Natural Science Foundation of Guizhou Province","doi-asserted-by":"publisher","award":["QJHRCTDZ [2015] 57"],"award-info":[{"award-number":["QJHRCTDZ [2015] 57"]}],"id":[{"id":"10.13039\/501100005329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005329","name":"Natural Science Foundation of Guizhou Province","doi-asserted-by":"publisher","award":["[2015]338"],"award-info":[{"award-number":["[2015]338"]}],"id":[{"id":"10.13039\/501100005329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21662010"],"award-info":[{"award-number":["21662010"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["201502030"],"award-info":[{"award-number":["201502030"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2019,3,28]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The state of histone acetylation plays a very crucial role in carcinogenesis and its development by chromatin remodeling and thus altering transcription of oncogenes and tumor suppressor genes. Such epigenetic regulation was controlled by zinc-dependent histone deacetylases (HDACs), one of the major regulators. Due to the therapeutic potential of HDACs as one of the promising drug targets in cancer, HDAC inhibitors have been intensively investigated over the last few decades. Notably, there are five HDAC inhibitors already approved to the market. Vorinostat (SAHA), Belinostat (PXD-101) and Romidepsin (FK228) have been approved by Food and Drug Administration (FDA) in USA for treating cutaneous T-cell lymphoma (CTCL) or peripheral T cell lymphoma (PTCL) while Panbinostat (LBH-589) has also been approved by the FDA for the treatment of multiple myeloma. Recently, Chidamide was approved by China Food and Drug Administration (CFDA) for the treatment of PTCL. The structural feature of almost all HDAC inhibitors consists of Cap group, linker, and zinc-binding group (ZBG). The binding of ZBG groups to zinc ion plays a decisive role in the inhibition of HDAC. Therefore, we will summarize the developed HDAC inhibitors according to different ZBG groups and discuss their binding mode with zinc ion.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1568026619666190122144949","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T08:00:40Z","timestamp":1548316840000},"page":"223-241","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups"],"prefix":"10.2174","volume":"19","author":[{"given":"Yan","family":"Li","sequence":"first","affiliation":[{"name":"State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang 550004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang 550004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang 550004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang 550004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglong","family":"Zhao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang 550004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang 550004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"He","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang 550004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0092-8674(04)00044-3","volume":"116","author":"Khorasanizadeh S.","year":"2004","unstructured":"Khorasanizadeh S. The nucleosome: from genomic organization to genomic regulation.","journal-title":"Cell"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature02625","volume":"429","author":"Egger G.","year":"2004","unstructured":"Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy.","journal-title":"Nature"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","volume":"358","author":"Esteller M.","year":"2008","unstructured":"Esteller M. Epigenetics in cancer.","journal-title":"N Engl J Med"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrm3890","volume":"15","author":"Tessarz P.","year":"2014","unstructured":"Tessarz P, Kouzarides T. Histone core modifications regulating nucleosome structure and dynamics.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4172\/2161-0444.1000252","volume":"5","author":"Kumar S.","year":"2015","unstructured":"Kumar S, Ahmad MK, Waseem M, Pandey AK. Drug targets for cancer treatment: An overview.","journal-title":"Med Chem"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"13708","DOI":"10.1073\/pnas.250477697","volume":"97","author":"Bernstein B.E.","year":"2000","unstructured":"Bernstein BE, Tong JK, Schreiber SL. Genomewide studies of histone deacetylase function in yeast.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","volume":"370","author":"de Ruijter A.J.M.","year":"2003","unstructured":"de Ruijter AJM, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): Characterization of the classical HDAC family.","journal-title":"Biochem J"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.gene.2005.09.010","volume":"363","author":"Glozak M.A.","year":"2005","unstructured":"Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins.","journal-title":"Gene"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ejmech.2018.08.073","volume":"158","author":"Sangwan R.","year":"2018","unstructured":"Sangwan R, Rajan R, Mandal PK. HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.","journal-title":"Eur J Med Chem"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jmb.2004.02.006","volume":"338","author":"Gregoretti I.V.","year":"2004","unstructured":"Gregoretti IV, Lee Y-M, Goodson HV. Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis.","journal-title":"J Mol Biol"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1101\/gad.1467506","volume":"20","author":"Haigis M.C.","year":"2006","unstructured":"Haigis MC, Guarente LP. Mammalian sirtuins-Emerging roles in physiology, aging, and calorie restriction.","journal-title":"Genes Dev"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(08)70004-4","volume":"9","author":"Weichert W.","year":"2008","unstructured":"Weichert W, R\u00f6ske A, Gekeler V, Beckers T, Ebert MP, Pross M, Dietel M, Denkert C, R\u00f6cken C. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: A retrospective analysis.","journal-title":"Lancet Oncol"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.bjc.6604199","volume":"98","author":"Weichert W.","year":"2008","unstructured":"Weichert W, R\u00f6ske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, Kristiansen G. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.","journal-title":"Br J Cancer"},{"key":"ref=14","first-page":"777","volume":"26","author":"Sudo T.","year":"2011","unstructured":"Sudo T, Mimori K, Nishida N, Kogo R, Iwaya T, Tanaka F, Shibata K, Fujita H, Shirouzu K, Mori M. Histone deacetylase 1 expression in gastric cancer.","journal-title":"Oncol Rep"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1158\/1078-0432.CCR-08-0684","volume":"15","author":"Oehme I.","year":"2009","unstructured":"Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, Kopp-Schneider A, Westermann F, Ulrich SM, von Deimling A, Fischer M, Witt O. Histone deacetylase 8 in neuroblastoma tumorigenesis.","journal-title":"Clin Cancer Res"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","volume":"124","author":"West A.C.","year":"2014","unstructured":"West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment.","journal-title":"J Clin Invest"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","volume":"13","author":"Falkenberg K.J.","year":"2014","unstructured":"Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.","journal-title":"Nat Rev Drug Discov"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","volume":"6","author":"Li Y.","year":"2016","unstructured":"Li Y, Seto E. HDACs and HDAC Inhibitors in cancer development and therapy.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","volume":"109","author":"Duvic M.","year":"2007","unstructured":"Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).","journal-title":"Blood"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","volume":"27","author":"Piekarz R.L.","year":"2009","unstructured":"Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, Stetler-Stevenson M, Lade S, Fojo AT, Bates SE. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.","journal-title":"J Clin Oncol"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1517\/13543784.2011.629604","volume":"20","author":"Molife L.R.","year":"2011","unstructured":"Molife LR, de Bono JS. Belinostat: Clinical applications in solid tumors and lymphoma.","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/17474086.2015.983065","volume":"8","author":"Libby E.N.","year":"2015","unstructured":"Libby EN, Becker PS, Burwick N, Green DJ, Holmberg L, Bensinger WI. Panobinostat: A review of trial results and future prospects in multiple myeloma.","journal-title":"Expert Rev Hematol"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2174\/156800961506150805153230","volume":"15","author":"Li Y.","year":"2015","unstructured":"Li Y, Chen K, Zhou Y, Xiao Y, Deng M, Jiang Z, Ye W, Wang X, Wei X, Li J, Liang J, Zheng Z, Yao Y, Wang W, Li P, Xu B. A new strategy to target acute myeloid leukemia stem and progenitor cells using chidamide, A histone deacetylase inhibitor.","journal-title":"Curr Cancer Drug Targets"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.str.2004.04.012","volume":"12","author":"Somoza J.R.","year":"2004","unstructured":"Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ, Luong C, Arvai A, Buggy JJ, Chi E, Tang J, Sang BC, Verner E, Wynands R, Leahy EM, Dougan DR, Snell G, Navre M, Knuth MW, Swanson RV, McRee DE, Tari LW. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases.","journal-title":"Structure"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"12474","DOI":"10.1021\/ja205972n","volume":"133","author":"Cole K.E.","year":"2011","unstructured":"Cole KE, Dowling DP, Boone MA, Phillips AJ, Christianson DW. Structural basis of the antiproliferative activity of largazole, A depsipeptide inhibitor of the histone deacetylases.","journal-title":"J Am Chem Soc"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1016\/j.bmc.2011.06.030","volume":"19","author":"Whitehead L.","year":"2011","unstructured":"Whitehead L, Dobler MR, Radetich B, Zhu Y, Atadja PW, Claiborne T, Grob JE, McRiner A, Pancost MR, Patnaik A, Shao W, Shultz M, Tichkule R, Tommasi RA, Vash B, Wang P, Stams T. Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors.","journal-title":"Bioorg Med Chem"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/43710","volume":"401","author":"Finnin M.S.","year":"1999","unstructured":"Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.","journal-title":"Nature"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1016\/j.bmc.2005.04.001","volume":"13","author":"Vanommeslaeghe K.","year":"2005","unstructured":"Vanommeslaeghe K, De Proft F, Loverix S, Tourw\u00e9 D, Geerlings P. Theoretical study revealing the functioning of a novel combination of catalytic motifs in histone deacetylase.","journal-title":"Bioorg Med Chem"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1021\/ja0600882","volume":"128","author":"Corminboeuf C.","year":"2006","unstructured":"Corminboeuf C, Hu P, Tuckerman ME, Zhang Y. Unexpected deacetylation mechanism suggested by a density functional theory QM\/MM study of histone-deacetylase-like protein.","journal-title":"J Am Chem Soc"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1021\/cb5003762","volume":"9","author":"Decroos C.","year":"2014","unstructured":"Decroos C, Bowman CM, Moser JA, Christianson KE, Deardorff MA, Christianson DW. Compromised structure and function of HDAC8 mutants identified in cornelia de lange syndrome spectrum disorders.","journal-title":"ACS Chem Biol"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.molcel.2013.05.020","volume":"51","author":"Millard C.J.","year":"2013","unstructured":"Millard CJ, Watson PJ, Celardo I, Gordiyenko Y, Cowley SM, Robinson CV, Fairall L, Schwabe JW, Class I, Class I. HDACs share a common mechanism of regulation by inositol phosphates.","journal-title":"Mol Cell"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1016\/j.bmcl.2010.03.091","volume":"20","author":"Bressi J.C.","year":"2010","unstructured":"Bressi JC, Jennings AJ, Skene R, Wu Y, Melkus R, De Jong R, O\u2019Connell S, Grimshaw CE, Navre M, Gangloff AR. Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"26926","DOI":"10.1074\/jbc.M113.490706","volume":"288","author":"Lauffer B.E.","year":"2013","unstructured":"Lauffer BE, Mintzer R, Fong R, Mukund S, Tam C, Zilberleyb I, Flicke B, Ritscher A, Fedorowicz G, Vallero R, Ortwine DF, Gunzner J, Modrusan Z, Neumann L, Koth CM, Lupardus PJ, Kaminker JS, Heise CE, Steiner P. Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.","journal-title":"J Biol Chem"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature10728","volume":"481","author":"Watson P.J.","year":"2012","unstructured":"Watson PJ, Fairall L, Santos GM, Schwabe JW. Structure of HDAC3 bound to co-repressor and inositol tetraphosphate.","journal-title":"Nature"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"26694","DOI":"10.1074\/jbc.M803514200","volume":"283","author":"Bottomley M.J.","year":"2008","unstructured":"Bottomley MJ, Lo Surdo P, Di Giovine P, Cirillo A, Scarpelli R, Ferrigno F, Jones P, Neddermann P, De Francesco R, Steink\u00fchler C, Gallinari P, Carf\u00ed A. Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain.","journal-title":"J Biol Chem"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"9934","DOI":"10.1021\/jm4011884","volume":"56","author":"B\u00fcrli R.W.","year":"2013","unstructured":"B\u00fcrli RW, Luckhurst CA, Aziz O, Matthews KL, Yates D, Lyons KA, Beconi M, McAllister G, Breccia P, Stott AJ, Penrose SD, Wall M, Lamers M, Leonard P, M\u00fcller I, Richardson CM, Jarvis R, Stones L, Hughes S, Wishart G, Haughan AF, O\u2019Connell C, Mead T, McNeil H, Vann J, Mangette J, Maillard M, Beaumont V, Munoz-Sanjuan I, Dominguez C. Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington\u2019s disease.","journal-title":"J Med Chem"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"11355","DOI":"10.1074\/jbc.M707362200","volume":"283","author":"Schuetz A.","year":"2008","unstructured":"Schuetz A, Min J, Allali-Hassani A, Schapira M, Shuen M, Loppnau P, Mazitschek R, Kwiatkowski NP, Lewis TA, Maglathin RL, McLean TH, Bochkarev A, Plotnikov AN, Vedadi M, Arrowsmith CH. Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity.","journal-title":"J Biol Chem"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nchembio.1223","volume":"9","author":"Lobera M.","year":"2013","unstructured":"Lobera M, Madauss KP, Pohlhaus DT, Wright QG, Trocha M, Schmidt DR, Baloglu E, Trump RP, Head MS, Hofmann GA, Murray-Thompson M, Schwartz B, Chakravorty S, Wu Z, Mander PK, Kruidenier L, Reid RA, Burkhart W, Turunen BJ, Rong JX, Wagner C, Moyer MB, Wells C, Hong X, Moore JT, Williams JD, Soler D, Ghosh S, Nolan MA. Selective class IIa histone deacetylase inhibition a nonchelating zinc-binding group.","journal-title":"Nat Chem Biol"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.embor.7401047","volume":"8","author":"Vannini A.","year":"2007","unstructured":"Vannini A, Volpari C, Gallinari P, Jones P, Mattu M, Carf\u00ed A, De Francesco R, Steink\u00fchler C, Di Marco S. Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex.","journal-title":"EMBO Rep"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.str.2004.04.012","volume":"12","author":"Somoza J.R.","year":"2004","unstructured":"Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ, Luong C, Arvai A, Buggy JJ, Chi E, Tang J, Sang BC, Verner E, Wynands R, Leahy EM, Dougan DR, Snell G, Navre M, Knuth MW, Swanson RV, McRee DE, Tari LW. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases.","journal-title":"Structure"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"15064","DOI":"10.1073\/pnas.0404603101","volume":"101","author":"Vannini A.","year":"2004","unstructured":"Vannini A, Volpari C, Filocamo G, Casavola EC, Brunetti M, Renzoni D, Chakravarty P, Paolini C, De Francesco R, Gallinari P, Steink\u00fchler C, Di Marco S. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1021\/bi1005046","volume":"49","author":"Dowling D.P.","year":"2010","unstructured":"Dowling DP, Gattis SG, Fierke CA, Christianson DW. Structures of metal-substituted human histone deacetylase 8 provide mechanistic inferences on biological function.","journal-title":"Biochemistry"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"13554","DOI":"10.1021\/bi801610c","volume":"47","author":"Dowling D.P.","year":"2008","unstructured":"Dowling DP, Gantt SL, Gattis SG, Fierke CA, Christianson DW. Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors.","journal-title":"Biochemistry"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.bmc.2007.10.092","volume":"16","author":"Sch\u00e4fer S.","year":"2008","unstructured":"Sch\u00e4fer S, Saunders L, Eliseeva E, Velena A, Jung M, Schwienhorst A, Strasser A, Dickmanns A, Ficner R, Schlimme S, Sippl W, Verdin E, Jung M. Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs).","journal-title":"Bioorg Med Chem"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1107\/S1744309107012377","volume":"63","author":"Nielsen T.K.","year":"2007","unstructured":"Nielsen TK, Hildmann C, Riester D, Wegener D, Schwienhorst A, Ficner R. Complex structure of a bacterial class 2 histone deacetylase homologue with a trifluoromethylketone inhibitor.","journal-title":"Acta Crystallogr Sect F Struct Biol Cryst Commun"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jmb.2005.09.065","volume":"354","author":"Nielsen T.K.","year":"2005","unstructured":"Nielsen TK, Hildmann C, Dickmanns A, Schwienhorst A, Ficner R. Crystal structure of a bacterial class 2 histone deacetylase homologue.","journal-title":"J Mol Biol"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.drudis.2015.01.007","volume":"20","author":"Micelli C.","year":"2015","unstructured":"Micelli C, Rastelli G. Histone deacetylases: Structural determinants of inhibitor selectivity.","journal-title":"Drug Discov Today"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/14756366.2017.1417274","volume":"33","author":"Zhang L.","year":"2018","unstructured":"Zhang L, Zhang J, Jiang Q, Zhang L, Song W. Zinc binding groups for histone deacetylase inhibitors.","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1039\/C4MD00401A","volume":"6","author":"Li Y.","year":"2015","unstructured":"Li Y, Woster PM. Discovery of a new class of histone deacetylase inhibitors with a novel zinc binding group.","journal-title":"MedChemComm"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/med.21320","volume":"35","author":"Zhang L.","year":"2015","unstructured":"Zhang L, Han Y, Jiang Q, Wang C, Chen X, Li X, Xu F, Jiang Y, Wang Q, Xu W. Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy.","journal-title":"Med Res Rev"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1016\/S0960-894X(02)00754-0","volume":"12","author":"Frey R.R.","year":"2002","unstructured":"Frey RR, Wada CK, Garland RB, Curtin ML, Michaelides MR, Li J, Pease LJ, Glaser KB, Marcotte PA, Bouska JJ, Murphy SS, Davidsen SK. Trifluoromethyl ketones as inhibitors of histone deacetylase.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1016\/j.bmcl.2004.04.083","volume":"14","author":"Reiter L.A.","year":"2004","unstructured":"Reiter LA, Robinson RP, McClure KF, Jones CS, Reese MR, Mitchell PG, Otterness IG, Bliven ML, Liras J, Cortina SR, Donahue KM, Eskra JD, Griffiths RJ, Lame ME, Lopez-Anaya A, Martinelli GJ, McGahee SM, Yocum SA, Lopresti-Morrow LL, Tobiassen LM, Vaughn-Bowser ML. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00775-004-0524-5","volume":"9","author":"Farkas E.","year":"2004","unstructured":"Farkas E, Katz Y, Bhusare S, Reich R, R\u00f6schenthaler GV, K\u00f6nigsmann M, Breuer E. Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: solution studies and stability constants. Towards a zinc-selective binding group.","journal-title":"J Biol Inorg Chem"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0162-0134(99)00245-7","volume":"79","author":"O\u2019Brien E.C.","year":"2000","unstructured":"O\u2019Brien EC, Farkas E, Gil MJ, Fitzgerald D, Castineras A, Nolan KB. Metal complexes of salicylhydroxamic acid (H2Sha), anthranilic hydroxamic acid and benzohydroxamic acid. Crystal and molecular structure of [Cu(phen)2(Cl)]Cl x H2Sha, a model for a peroxidase-inhibitor complex.","journal-title":"J Inorg Biochem"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"287","DOI":"10.21037\/atm.2016.07.22","volume":"4","author":"Clawson G.A.","year":"2016","unstructured":"Clawson GA. Histone deacetylase inhibitors as cancer therapeutics.","journal-title":"Ann Transl Med"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.2174\/092986705774454706","volume":"12","author":"Suzuki T.","year":"2005","unstructured":"Suzuki T, Miyata N. Non-hydroxamate histone deacetylase inhibitors.","journal-title":"Curr Med Chem"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7164\/antibiotics.29.1","volume":"29","author":"Tsuji N.","year":"1976","unstructured":"Tsuji N, Kobayashi M, Nagashima K, Wakisaka Y, Koizumi K. A new antifungal antibiotic, trichostatin.","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1016\/S0021-9258(17)44885-X","volume":"265","author":"Yoshida M.","year":"1990","unstructured":"Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both and by trichostatin A.","journal-title":"J Biol Chem"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nchembio.313","volume":"6","author":"Bradner J.E.","year":"2010","unstructured":"Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, Mazitschek R. Chemical phylogenetics of histone deacetylases.","journal-title":"Nat Chem Biol"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1021\/jm7011408","volume":"51","author":"Paris M.","year":"2008","unstructured":"Paris M, Porcelloni M, Binaschi M, Fattori D. Histone deacetylase inhibitors: From bench to clinic.","journal-title":"J Med Chem"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1042\/BST0380445","volume":"38","author":"Tam G.W.","year":"2010","unstructured":"Tam GW, van de Lagemaat LN, Redon R, Strathdee KE, Croning MD, Malloy MP, Muir WJ, Pickard BS, Deary IJ, Blackwood DH, Carter NP, Grant SG. Confirmed rare copy number variants implicate novel genes in schizophrenia.","journal-title":"Biochem Soc Trans"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1042\/BJ20070779","volume":"409","author":"Khan N.","year":"2008","unstructured":"Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.","journal-title":"Biochem J"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1073\/pnas.95.6.3003","volume":"95","author":"Richon V.M.","year":"1998","unstructured":"Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.2174\/0929867322666150416094720","volume":"22","author":"Bian J.","year":"2015","unstructured":"Bian J, Zhang L, Han Y, Wang C, Zhang L. Histone deacetylase inhibitors: potent anti-leukemic agents.","journal-title":"Curr Med Chem"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.4155\/fmc.12.80","volume":"4","author":"Giannini G.","year":"2012","unstructured":"Giannini G, Cabri W, Fattorusso C, Rodriquez M. Histone deacetylase inhibitors in the treatment of cancer: Cverview and perspectives.","journal-title":"Future Med Chem"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/ars.2013.5776","volume":"23","author":"Benedetti R.","year":"2015","unstructured":"Benedetti R, Conte M, Altucci L. Targeting histone deacetylases in diseases: Where are we?","journal-title":"Antioxid Redox Signal"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/nrd2681","volume":"7","author":"Kazantsev A.G.","year":"2008","unstructured":"Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders.","journal-title":"Nat Rev Drug Discov"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","volume":"119","author":"Santo L.","year":"2012","unstructured":"Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, Cirstea D, Rodig S, Eda H, Scullen T, Canavese M, Bradner J, Anderson KC, Jones SS, Raje N. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.","journal-title":"Blood"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1158\/1535-7163.MCT-09-0689","volume":"9","author":"Novotny-Diermayr V.","year":"2010","unstructured":"Novotny-Diermayr V, Sangthongpitag K, Hu CY, Wu X, Sausgruber N, Yeo P, Greicius G, Pettersson S, Liang AL, Loh YK, Bonday Z, Goh KC, Hentze H, Hart S, Wang H, Ethirajulu K, Wood JM. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.","journal-title":"Mol Cancer Ther"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/pbc.24694","volume":"60","author":"Zorzi A.P.","year":"2013","unstructured":"Zorzi AP, Bernstein M, Samson Y, Wall DA, Desai S, Nicksy D, Wainman N, Eisenhauer E, Baruchel S. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program\/C17 pediatric phase I consortium.","journal-title":"Pediatr Blood Cancer"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1365-2141.2010.08124.x","volume":"149","author":"Mandl-Weber S.","year":"2010","unstructured":"Mandl-Weber S, Meinel FG, Jankowsky R, Oduncu F, Schmidmaier R, Baumann P. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.","journal-title":"Br J Haematol"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10637-017-0435-2","volume":"35","author":"Tambo Y.","year":"2017","unstructured":"Tambo Y, Hosomi Y, Sakai H, Nogami N, Atagi S, Sasaki Y, Kato T, Takahashi T, Seto T, Maemondo M, Nokihara H, Koyama R, Nakagawa K, Kawaguchi T, Okamura Y, Nakamura O, Nishio M, Tamura T. Phase I\/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.","journal-title":"Invest New Drugs"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1158\/1535-7163.MCT-05-0442","volume":"5","author":"Buggy J.J.","year":"2006","unstructured":"Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, Liu L, Schultz BE, Young PR, Dalrymple SA. CRA-024781: A novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity and","journal-title":"Mol Cancer Ther"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjd.14427","volume":"175","author":"Child F.","year":"2016","unstructured":"Child F, Ortiz-Romero PL, Alvarez R, Bagot M, Stadler R, Weichenthal M, Alves R, Quaglino P, Beylot-Barry M, Cowan R, Geskin LJ, P\u00e9rez-Ferriols A, Hellemans P, Elsayed Y, Phelps C, Forslund A, Kamida M, Zinzani PL. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides\/S\u00e9zary syndrome.","journal-title":"Br J Dermatol"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"6841","DOI":"10.1158\/1078-0432.CCR-09-0547","volume":"15","author":"Arts J.","year":"2009","unstructured":"Arts J, King P, Mari\u00ebn A, Floren W, Beli\u00ebn A, Janssen L, Pilatte I, Roux B, Decrane L, Gilissen R, Hickson I, Vreys V, Cox E, Bol K, Talloen W, Goris I, Andries L, Du Jardin M, Janicot M, Page M, van Emelen K, Angibaud P. JNJ-26481585, A novel \u201csecond-generation\u201d oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.","journal-title":"Clin Cancer Res"},{"key":"ref=76","first-page":"489","volume":"15","author":"Kouraklis G.","year":"2006","unstructured":"Kouraklis G, Theocharis S. Histone deacetylase inhibitors: a novel target of anticancer therapy.(review).","journal-title":"Oncol Rep"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"8663","DOI":"10.1021\/jm101177s","volume":"53","author":"Moffat D.","year":"2010","unstructured":"Moffat D, Patel S, Day F, Belfield A, Donald A, Rowlands M, Wibawa J, Brotherton D, Stimson L, Clark V, Owen J, Bawden L, Box G, Bone E, Mortenson P, Hardcastle A, van Meurs S, Eccles S, Raynaud F, Aherne W. Discovery of 2-(6-[(6-fluoroquinolin-2-yl) methyl] amino bicyclo [3.1.0] hex-3-yl)-Nhydroxypyrimidine-5-carboxamide (CHR-3996), A class I selective orally active histone deacetylase inhibitor.","journal-title":"J Med Chem"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1158\/1078-0432.CCR-11-3165","volume":"18","author":"Banerji U.","year":"2012","unstructured":"Banerji U, van Doorn L, Papadatos-Pastos D, Kristeleit R, Debnam P, Tall M, Stewart A, Raynaud F, Garrett MD, Toal M, Hooftman L, De Bono JS, Verweij J, Eskens FA. A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors.","journal-title":"Clin Cancer Res"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/bjh.12359","volume":"162","author":"Ossenkoppele G.J.","year":"2013","unstructured":"Ossenkoppele GJ, Lowenberg B, Zachee P, Vey N, Breems D, Van de Loosdrecht AA, Davidson AH, Wells G, Needham L, Bawden L, Toal M, Hooftman L, Debnam PM. A phase I first-in-human study with tefinostat - a monocyte\/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies.","journal-title":"Br J Haematol"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/lary.22392","volume":"122","author":"Jacob A.","year":"2012","unstructured":"Jacob A, Oblinger J, Bush ML, Brendel V, Santarelli G, Chaudhury AR, Kulp S, La Perle KM, Chen CS, Chang LS, Welling DB. Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas.","journal-title":"Laryngoscope"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/bjc.2011.527","volume":"106","author":"Pili R.","year":"2012","unstructured":"Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J, Carducci MA, Rudek MA. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.","journal-title":"Br J Cancer"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/1078-0432.CCR-14-2820","volume":"21","author":"Galloway T.J.","year":"2015","unstructured":"Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A. A phase I study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma.","journal-title":"Clin Cancer Res"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.3390\/molecules20033898","volume":"20","author":"Mottamal M.","year":"2015","unstructured":"Mottamal M, Zheng S, Huang TL, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.","journal-title":"Molecules"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1021\/jm401945k","volume":"57","author":"Fleming C.L.","year":"2014","unstructured":"Fleming CL, Ashton TD, Gaur V, McGee SL, Pfeffer FM. Improved synthesis and structural reassignment of MC1568: A class IIa selective HDAC inhibitor.","journal-title":"J Med Chem"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1021\/jm401899x","volume":"57","author":"Lee H.Y.","year":"2014","unstructured":"Lee HY, Tsai AC, Chen MC, Shen PJ, Cheng YC, Kuo CC, Pan SL, Liu YM, Liu JF, Yeh TK, Wang JC, Chang CY, Chang JY, Liou JP. Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.","journal-title":"J Med Chem"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1021\/acs.jmedchem.5b00126","volume":"58","author":"Di Pompo G.","year":"2015","unstructured":"Di Pompo G, Salerno M, Rotili D, Valente S, Zwergel C, Avnet S, Lattanzi G, Baldini N, Mai A. Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells.","journal-title":"J Med Chem"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"9357","DOI":"10.1021\/jm5012148","volume":"57","author":"Yang F.","year":"2014","unstructured":"Yang F, Zhang T, Wu H, Yang Y, Liu N, Chen A, Li Q, Li J, Qin L, Jiang B, Wang X, Pang X, Yi Z, Liu M, Chen Y. Design and optimization of novel hydroxamate-based histone deacetylase inhibitors of Bis-substituted aromatic amides bearing potent activities against tumor growth and metastasis.","journal-title":"J Med Chem"},{"key":"ref=88","author":"Abeywickrama C.","year":"2015","unstructured":"Abeywickrama C, Bradner JE, Ponnala S. Dana-farber cancer institute. selective inhibitors for histone deacetylase 6 and method thereof US, 20150197497, August 16"},{"key":"ref=89","author":"Qin H-T.","year":"2015","unstructured":"Qin H-T, Li H-Q, Liu F. Trustees of boston university. selective histone deacetylase 8 inhibitors US, 20150352079, December 10"},{"key":"ref=90","author":"Dominguez C.","year":"2016","unstructured":"Dominguez C, Mu\u00f1oz-Sanju\u00e1n I, Maillard M, Raphy G, Haughan AF, Luckhurst CA, Jarvis RE, B\u00fcrli RW, Breccia P, Wishart G, Hughes SJ, Allen DR, Penrose SD. CHDI Foundation Inc.Histone deacetylase inhibitors and compositions and methods of use thereof US, 20160031863, February 4"},{"key":"ref=91","author":"Dominguez C.","year":"2016","unstructured":"Dominguez C, Mu\u00f1oz-Sanju\u00e1n I, Maillard M, Raphy G, Haughan AF, Luckhurst CA, Jarvis RE, B\u00fcrli RW, Wishart G, Hughes SJ, Allen DR, Penrose SD. Breccia, P. CHDI Foundation Inc. Histone deacetylase inhibitors and compositions and methods of use thereof US, 20160039745, February 11"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1021\/acs.jmedchem.6b00579","volume":"59","author":"Chen Y.","year":"2016","unstructured":"Chen Y, Wang X, Xiang W, He L, Tang M, Wang F, Wang T, Yang Z, Yi Y, Wang H, Niu T, Zheng L, Lei L, Li X, Song H, Chen L. Development of purine-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked and antitumor activities.","journal-title":"J Med Chem"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"35402","DOI":"10.1074\/jbc.M807045200","volume":"283","author":"Chou C.J.","year":"2008","unstructured":"Chou CJ, Herman D, Gottesfeld JM. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases.","journal-title":"J Biol Chem"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1042\/BJ20070779","volume":"409","author":"Khan N.","year":"2008","unstructured":"Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.","journal-title":"Biochem J"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1016\/j.bmc.2016.06.040","volume":"24","author":"Wagner F.F.","year":"2016","unstructured":"Wagner FF, We\u00efwer M, Steinbacher S, Schomburg A, Reinemer P, Gale JP, Campbell AJ, Fisher SL, Zhao WN, Reis SA, Hennig KM, Thomas M, M\u00fcller P, Jefson MR, Fass DM, Haggarty SJ, Zhang YL, Holson EB. Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors.","journal-title":"Bioorg Med Chem"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1182\/blood-2006-05-021873","volume":"109","author":"Gojo I.","year":"2007","unstructured":"Gojo I, Jiemjit A, Trepel JB, Sparreboom A, Figg WD, Rollins S, Tidwell ML, Greer J, Chung EJ, Lee MJ, Gore SD, Sausville EA, Zwiebel J, Karp JE. Phase 1 and pharmacologic study of MS-275, A histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.","journal-title":"Blood"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1158\/1078-0432.CCR-07-4427","volume":"14","author":"Bonfils C.","year":"2008","unstructured":"Bonfils C, Kalita A, Dubay M, Siu LL, Carducci MA, Reid G, Martell RE, Besterman JM, Li Z. Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay.","journal-title":"Clin Cancer Res"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2141.2009.07881.x","volume":"147","author":"Blum K.A.","year":"2009","unstructured":"Blum KA, Advani A, Fernandez L, Van Der Jagt R, Brandwein J, Kambhampati S, Kassis J, Davis M, Bonfils C, Dubay M, Dumouchel J, Drouin M, Lucas DM, Martell RE, Byrd JC. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia.","journal-title":"Br J Haematol"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2007-10-115873","volume":"112","author":"Garcia-Manero G.","year":"2008","unstructured":"Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, Newsome WM, Miller WH, Rousseau C, Kalita A, Bonfils C, Dubay M, Patterson TA, Li Z, Besterman JM, Reid G, Laille E, Martell RE, Minden M. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.","journal-title":"Blood"},{"key":"ref=100","author":"Holson E.","year":"2015","unstructured":"Holson E, Wagner FF, Haggarty SJ, Zhang Y-L, Lundh M, Wagner B, Lewis MC. The general hospital corporation d\/b\/a massachusetts general hospital. inhibitors of histone deacetylase US, 20150191427, August 9,"},{"key":"ref=101","author":"Harrington P.","year":"2013","unstructured":"Harrington P. 4-carboxy-benzylamino derivatives as histone deacetylase inhibitors US, 20130137690, May 30"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1073\/pnas.1213364110","volume":"110","author":"Malvaez M.","year":"2013","unstructured":"Malvaez M, McQuown SC, Rogge GA, Astarabadi M, Jacques V, Carreiro S, Rusche JR, Wood MA. HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=103","author":"Grigg R.E.","year":"2014","unstructured":"Grigg RE, Inman M, Packham G. Cancer research technology Ltd. N-(2-aminophenyl) benzamide derivatives as histone deacetylase inhibitors US, 20140135327, February 6,"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1021\/acs.jmedchem.5b00545","volume":"58","author":"Marson C.M.","year":"2015","unstructured":"Marson CM, Matthews CJ, Atkinson SJ, Lamadema N, Thomas NS. Potent and selective inhibitors of histone deacetylase-3 containing chiral oxazoline capping groups and a N-(2-Aminophenyl)-benzamide binding unit.","journal-title":"J Med Chem"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1021\/np400198r","volume":"76","author":"Pavlik C.M.","year":"2013","unstructured":"Pavlik CM, Wong CYB, Ononye S, Lopez DD, Engene N, McPhail KL, Gerwick WH, Balunas MJ. Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium Symploca sp.","journal-title":"J Nat Prod"},{"key":"ref=106","author":"Balunas M.J.","year":"2014","unstructured":"Balunas MJ. PAVLIK, C.M.; Gerwick, W.H. University of connecticut. santacruzamate a composition and analogs and methods of use W0, 2014018913, January 30"},{"key":"ref=107","author":"Jacques V.","year":"2014","unstructured":"Jacques V, Rusche JR, Peet NP, Singh J. Repligen corporation. histone deacetylase inhibitor US, 20140051680, February 20"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.nbd.2012.01.016","volume":"46","author":"Jia H.","year":"2012","unstructured":"Jia H, Pallos J, Jacques V, Lau A, Tang B, Cooper A, Syed A, Purcell J, Chen Y, Sharma S, Sangrey GR, Darnell SB, Plasterer H, Sadri-Vakili G, Gottesfeld JM, Thompson LM, Rusche JR, Marsh JL, Thomas EA. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington\u2019s disease.","journal-title":"Neurobiol Dis"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"8903","DOI":"10.1021\/jm3011838","volume":"55","author":"Wong J.C.","year":"2012","unstructured":"Wong JC, Tang G, Wu X, Liang C, Zhang Z, Guo L, Peng Z, Zhang W, Lin X, Wang Z, Mei J, Chen J, Pan S, Zhang N, Liu Y, Zhou M, Feng L, Zhao W, Li S, Zhang C, Zhang M, Rong Y, Jin TG, Zhang X, Ren S, Ji Y, Zhao R, She J, Ren Y, Xu C, Chen D, Cai J, Shan S, Pan D, Ning Z, Lu X, Chen T, He Y, Chen L. Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.","journal-title":"J Med Chem"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"6259","DOI":"10.1021\/jm500303u","volume":"57","author":"Valente S.","year":"2014","unstructured":"Valente S, Trisciuoglio D, De Luca T, Nebbioso A, Labella D, Lenoci A, Bigogno C, Dondio G, Miceli M, Brosch G, Del Bufalo D, Altucci L, Mai A. 1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells.","journal-title":"J Med Chem"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"12474","DOI":"10.1021\/ja205972n","volume":"133","author":"Cole K.E.","year":"2011","unstructured":"Cole KE, Dowling DP, Boone MA, Phillips AJ, Christianson DW. Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases.","journal-title":"J Am Chem Soc"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1021\/ml300371t","volume":"4","author":"Li X.","year":"2012","unstructured":"Li X, Tu Z, Li H, Liu C, Li Z, Sun Q, Yao Y, Liu J, Jiang S. Biological evaluation of new largazole analogues: alteration of macrocyclic scaffold with click chemistry.","journal-title":"ACS Med Chem Lett"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1021\/ml400470s","volume":"5","author":"Chen F.","year":"2014","unstructured":"Chen F, Chai H, Su MB, Zhang YM, Li J, Xie X, Nan FJ. Potent and orally efficacious bisthiazole-based histone deacetylase inhibitors.","journal-title":"ACS Med Chem Lett"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejmech.2016.02.003","volume":"112","author":"Gong C.J.","year":"2016","unstructured":"Gong CJ, Gao AH, Zhang YM, Su MB, Chen F, Sheng L, Zhou YB, Li JY, Li J, Nan FJ. Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy.","journal-title":"Eur J Med Chem"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1016\/j.bmcl.2004.03.063","volume":"14","author":"Suzuki T.","year":"2004","unstructured":"Suzuki T, Kouketsu A, Matsuura A, Kohara A, Ninomiya S, Kohda K, Miyata N. Thiol-based SAHA analogues as potent histone deacetylase inhibitors.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1021\/ol036098e","volume":"5","author":"Nishino N.","year":"2003","unstructured":"Nishino N, Jose B, Okamura S, Ebisusaki S, Kato T, Sumida Y, Yoshida M. Cyclic tetrapeptides bearing a sulfhydryl group potently inhibit histone deacetylases.","journal-title":"Org Lett"},{"key":"ref=117","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bmcl.2015.12.007","volume":"26","author":"Wen J.","year":"2016","unstructured":"Wen J, Niu Q, Liu J, Bao Y, Yang J, Luan S, Fan Y, Liu D, Zhao L. Novel thiol-based histone deacetylase inhibitors bearing 3-phenyl-1H-pyrazole-5-carboxamide scaffold as surface recognition motif: Design, synthesis and SAR study.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=118","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1021\/jm060554y","volume":"49","author":"Suzuki T.","year":"2006","unstructured":"Suzuki T, Kouketsu A, Itoh Y, Hisakawa S, Maeda S, Yoshida M, Nakagawa H, Miyata N. Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate.","journal-title":"J Med Chem"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"8358","DOI":"10.1021\/jm5008209","volume":"57","author":"Giannini G.","year":"2014","unstructured":"Giannini G, Vesci L, Battistuzzi G, Vignola D, Milazzo FM, Guglielmi MB, Barbarino M, Santaniello M, Fant\u00f2 N, Mor M, Rivara S, Pala D, Taddei M, Pisano C, Cabri W. ST7612AA1, a thioacetate-\u03c9(\u03b3-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors.","journal-title":"J Med Chem"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.18632\/oncotarget.3240","volume":"6","author":"Vesci L.","year":"2015","unstructured":"Vesci L, Bernasconi E, Milazzo FM, De Santis R, Gaudio E, Kwee I, Rinaldi A, Pace S, Carollo V, Giannini G, Bertoni F. Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor.","journal-title":"Oncotarget"},{"key":"ref=121","doi-asserted-by":"crossref","first-page":"282","DOI":"10.2174\/1573407212666160504160556","volume":"12","author":"Battistuzzi G.","year":"2016","unstructured":"Battistuzzi G, Giannini G. Synthesis of ST7612AA1, A novel oral HDAC inhibitor, radical thioacetic acid addition.","journal-title":"Curr Bioact Compd"},{"key":"ref=122","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.molcel.2013.05.020","volume":"51","author":"Millard C.J.","year":"2013","unstructured":"Millard CJ, Watson PJ, Celardo I, Gordiyenko Y, Cowley SM, Robinson CV, Fairall L, Schwabe JWR, Class I, Class I. HDACs share a common mechanism of regulation by inositol phosphates.","journal-title":"Mol Cell"},{"key":"ref=123","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature10728","volume":"481","author":"Watson P.J.","year":"2012","unstructured":"Watson PJ, Fairall L, Santos GM, Schwabe JW. Structure of HDAC3 bound to co-repressor and inositol tetraphosphate.","journal-title":"Nature"},{"key":"ref=124","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jmb.2005.09.065","volume":"354","author":"Nielsen T.K.","year":"2005","unstructured":"Nielsen TK, Hildmann C, Dickmanns A, Schwienhorst A, Ficner R. Crystal structure of a bacterial class 2 histone deacetylase homologue.","journal-title":"J Mol Biol"},{"key":"ref=125","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ijrobp.2015.04.038","volume":"92","author":"Krauze A.V.","year":"2015","unstructured":"Krauze AV, Myrehaug SD, Chang MG, Holdford DJ, Smith S, Shih J, Tofilon PJ, Fine HA, Camphausen K. A phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref=126","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1182\/blood-2013-12-546283","volume":"123","author":"Tassara M.","year":"2014","unstructured":"Tassara M, D\u00f6hner K, Brossart P, Held G, G\u00f6tze K, Horst HA, Ringhoffer M, K\u00f6hne CH, Kremers S, Raghavachar A, Wulf G, Kirchen H, Nachbaur D, Derigs HG, Wattad M, Koller E, Brugger W, Matzdorff A, Greil R, Heil G, Paschka P, Gaidzik VI, G\u00f6ttlicher M, D\u00f6hner H, Schlenk RF. Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients.","journal-title":"Blood"},{"key":"ref=127","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/ijc.2910560625","volume":"56","author":"Aviram A.","year":"1994","unstructured":"Aviram A, Zimrah Y, Shaklai M, Nudelman A, Rephaeli A. Comparison between the effect of butyric acid and its prodrug pivaloyloxymethylbutyrate on histones hyperacetylation in an HL-60 leukemic cell line.","journal-title":"Int J Cancer"},{"key":"ref=128","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s13277-015-3781-8","volume":"37","author":"Kusaczuk M.","year":"2016","unstructured":"Kusaczuk M, Kr\u0119towski R, Bartoszewicz M, Cechowska-Pasko M. Phenylbutyrate-a pan-HDAC inhibitor-suppresses proliferation of glioblastoma LN-229 cell line.","journal-title":"Tumour Biol"},{"key":"ref=129","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1016\/j.bmcl.2004.04.083","volume":"14","author":"Reiter L.A.","year":"2004","unstructured":"Reiter LA, Robinson RP, McClure KF, Jones CS, Reese MR, Mitchell PG, Otterness IG, Bliven ML, Liras J, Cortina SR, Donahue KM, Eskra JD, Griffiths RJ, Lame ME, Lopez-Anaya A, Martinelli GJ, McGahee SM, Yocum SA, Lopresti-Morrow LL, Tobiassen LM, Vaughn-Bowser ML. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=130","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00775-004-0524-5","volume":"9","author":"Farkas E.","year":"2004","unstructured":"Farkas E, Katz Y, Bhusare S, Reich R, R\u00f6schenthaler GV, K\u00f6nigsmann M, Breuer E. Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: Solution studies and stability constants. Towards a zinc-selective binding group.","journal-title":"J Biol Inorg Chem"},{"key":"ref=131","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0162-0134(99)00245-7","volume":"79","author":"O\u2019Brien E.C.","year":"2000","unstructured":"O\u2019Brien EC, Farkas E, Gil MJ, Fitzgerald D, Castineras A, Nolan KB. Metal complexes of salicylhydroxamic acid (H2Sha), anthranilic hydroxamic acid and benzohydroxamic acid. Crystal and molecular structure of [Cu(phen)2(Cl)]Cl x H2Sha, a model for a peroxidase-inhibitor complex.","journal-title":"J Inorg Biochem"},{"key":"ref=132","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.2174\/092986705774454706","volume":"12","author":"Suzuki T.","year":"2005","unstructured":"Suzuki T, Miyata N. Non-hydroxamate histone deacetylase inhibitors.","journal-title":"Curr Med Chem"},{"key":"ref=133","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/14756366.2017.1417274","volume":"33","author":"Zhang L.","year":"2018","unstructured":"Zhang L, Zhang J, Jiang Q, Zhang L, Song W. Zinc binding groups for histone deacetylase inhibitors.","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=134","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ejmech.2016.05.047","volume":"121","author":"Roche J.","year":"2016","unstructured":"Roche J, Bertrand P. Inside HDACs with more selective HDAC inhibitors.","journal-title":"Eur J Med Chem"},{"key":"ref=135","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1124\/jpet.103.055541","volume":"307","author":"Hu E.","year":"2003","unstructured":"Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF, Johanson K, Liu R, Lago A, Hofmann G, Macarron R, de los Frailes M, Perez P, Krawiec J, Winkler J, Jaye M. Identification of novel isoform-selective inhibitors within class I histone deacetylases.","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=136","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1002\/cmdc.201600528","volume":"11","author":"Kleinschek A.","year":"2016","unstructured":"Kleinschek A, Meyners C, Digiorgio E, Brancolini C, Meyer-Almes FJ. Potent and selective non-hydroxamate histone deacetylase 8 inhibitors.","journal-title":"ChemMedChem"},{"key":"ref=137","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1021\/ml400158k","volume":"4","author":"Ononye S.N.","year":"2013","unstructured":"Ononye SN, VanHeyst MD, Oblak EZ, Zhou W, Ammar M, Anderson AC, Wright DL. Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors.","journal-title":"ACS Med Chem Lett"},{"key":"ref=138","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1021\/jm301769u","volume":"56","author":"Patil V.","year":"2013","unstructured":"Patil V, Sodji QH, Kornacki JR, Mrksich M, Oyelere AK. 3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition.","journal-title":"J Med Chem"},{"key":"ref=139","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1016\/j.bmcl.2009.04.011","volume":"19","author":"Attenni B.","year":"2009","unstructured":"Attenni B, Ontoria JM, Cruz JC, Rowley M, Schultz-Fademrecht C, Steink\u00fchler C, Jones P. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=140","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1039\/C1MD00249J","volume":"3","author":"Valente S.","year":"2012","unstructured":"Valente S, Conte M, Tardugno M, Nebbioso A, Tinari G, Altucci L, Mai A. Developing novel non-hydroxamate histone deacetylase inhibitors: the chelidamic warhead.","journal-title":"MedChemComm"},{"key":"ref=141","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.chembiol.2014.12.015","volume":"22","author":"Wang Y.","year":"2015","unstructured":"Wang Y, Stowe RL, Pinello CE, Tian G, Madoux F, Li D, Zhao LY, Li JL, Wang Y, Wang Y, Ma H, Hodder P, Roush WR, Liao D. Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases.","journal-title":"Chem Biol"},{"key":"ref=142","doi-asserted-by":"crossref","first-page":"9942","DOI":"10.1021\/acs.jmedchem.6b01385","volume":"59","author":"McClure J.J.","year":"2016","unstructured":"McClure JJ, Zhang C, Inks ES, Peterson YK, Li J, Chou CJ. Development of allosteric hydrazide-containing class I histone deacetylase inhibitors for use in acute myeloid leukemia.","journal-title":"J Med Chem"},{"key":"ref=143","doi-asserted-by":"crossref","first-page":"29086","DOI":"10.1038\/srep29086","volume":"6","author":"Goracci L.","year":"2016","unstructured":"Goracci L, Deschamps N, Randazzo GM, Petit C, Dos Santos Passos C, Carrupt PA, Sim\u00f5es-Pires C, Nurisso A. A rational approach for the identification of non-hydroxamate hdac6-selective inhibitors.","journal-title":"Sci Rep"},{"key":"ref=144","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nchembio.1223","volume":"9","author":"Lobera M.","year":"2013","unstructured":"Lobera M, Madauss KP, Pohlhaus DT, Wright QG, Trocha M, Schmidt DR, Baloglu E, Trump RP, Head MS, Hofmann GA, Murray-Thompson M, Schwartz B, Chakravorty S, Wu Z, Mander PK, Kruidenier L, Reid RA, Burkhart W, Turunen BJ, Rong JX, Wagner C, Moyer MB, Wells C, Hong X, Moore JT, Williams JD, Soler D, Ghosh S, Nolan MA. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group.","journal-title":"Nat Chem Biol"},{"key":"ref=145","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1021\/ci500762z","volume":"55","author":"Hou X.","year":"2015","unstructured":"Hou X, Du J, Liu R, Zhou Y, Li M, Xu W, Fang H. Enhancing the sensitivity of pharmacophore-based virtual screening by incorporating customized ZBG features: A case study using histone deacetylase 8.","journal-title":"J Chem Inf Model"},{"key":"ref=146","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejmech.2016.02.003","volume":"112","author":"Gong C.J.","year":"2016","unstructured":"Gong CJ, Gao AH, Zhang YM, Su MB, Chen F, Sheng L, Zhou YB, Li JY, Li J, Nan FJ. Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy.","journal-title":"Eur J Med Chem"},{"key":"ref=147","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1039\/C4MD00401A","volume":"6","author":"Li Y.","year":"2015","unstructured":"Li Y, Woster PM. Discovery of a new class of histone deacetylase inhibitors with a novel zinc binding group.","journal-title":"MedChemComm"},{"key":"ref=148","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1016\/j.bmcl.2011.05.098","volume":"21","author":"Kemp M.M.","year":"2011","unstructured":"Kemp MM, Wang Q, Fuller JH, West N, Martinez NM, Morse EM, We\u00efwer M, Schreiber SL, Bradner JE, Koehler AN. A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=149","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1021\/cb500767c","volume":"10","author":"Zhou J.","year":"2015","unstructured":"Zhou J, Li M, Chen N, Wang S, Luo HB, Zhang Y, Wu R. Computational design of a time-dependent histone deacetylase 2 selective inhibitor.","journal-title":"ACS Chem Biol"},{"key":"ref=150","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1021\/acschembio.6b00012","volume":"11","author":"Boskovic Z.V.","year":"2016","unstructured":"Boskovic ZV, Kemp MM, Freedy AM, Viswanathan VS, Pop MS, Fuller JH, Martinez NM, Figueroa Laz\u00fa SO, Hong JA, Lewis TA, Calarese D, Love JD, Vetere A, Almo SC, Schreiber SL, Koehler AN. Figueroa, Laz\u00fa, S.O.; Hong, J.A.; Lewis, T.A.; Calarese, D.; Love, J.D.; Vetere, A.; Almo, S.C.; Schreiber, S.L.; Koehler, A.N. Inhibition of zinc-dependent histone deacetylases with a chemically triggered electrophile.","journal-title":"ACS Chem Biol"},{"key":"ref=151","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3892\/or.2012.1870","volume":"28","author":"Orlikova B.","year":"2012","unstructured":"Orlikova B, Schnekenburger M, Zloh M, Golais F, Diederich M, Tasdemir D. Natural chalcones as dual inhibitors of HDACs and NF-\u03baB.","journal-title":"Oncol Rep"},{"key":"ref=152","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jnutbio.2012.07.001","volume":"24","author":"Berger A.","year":"2013","unstructured":"Berger A, Venturelli S, Kallnischkies M, B\u00f6cker A, Busch C, Weiland T, Noor S, Leischner C, Weiss TS, Lauer UM, Bischoff SC, Bitzer M. Kaempferol, a new nutrition-derived pan-inhibitor of human histone deacetylases.","journal-title":"J Nutr Biochem"},{"key":"ref=153","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/1472-6882-13-232","volume":"13","author":"Senawong T.","year":"2013","unstructured":"Senawong T, Misuna S, Khaopha S, Nuchadomrong S, Sawatsitang P, Phaosiri C, Surapaitoon A, Sripa B. Histone deacetylase (HDAC) inhibitory and antiproliferative activities of phenolic-rich extracts derived from the rhizome of Hydnophytum formicarum Jack.: sinapinic acid acts as HDAC inhibitor.","journal-title":"BMC Complement Altern Med"},{"key":"ref=154","doi-asserted-by":"crossref","first-page":"e73097","DOI":"10.1371\/journal.pone.0073097","volume":"8","author":"Venturelli S.","year":"2013","unstructured":"Venturelli S, Berger A, B\u00f6cker A, Busch C, Weiland T, Noor S, Leischner C, Schleicher S, Mayer M, Weiss TS, Bischoff SC, Lauer UM, Bitzer M. Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells.","journal-title":"PLoS One"},{"key":"ref=155","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0092-8674(80)90357-8","volume":"22","author":"McKnight G.S.","year":"1980","unstructured":"McKnight GS, Hager L, Palmiter RD. Butyrate and related inhibitors of histone deacetylation block the induction of egg white genes by steroid hormones.","journal-title":"Cell"},{"key":"ref=156","doi-asserted-by":"crossref","first-page":"E1608","DOI":"10.3390\/molecules21111608","volume":"21","author":"Losson H.","year":"2016","unstructured":"Losson H, Schnekenburger M, Dicato M, Diederich M. Natural compound histone deacetylase inhibitors (hdaci): synergy with inflammatory signaling pathway modulators and clinical applications in cancer.","journal-title":"Molecules"},{"key":"ref=157","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1055\/s-0034-1396149","volume":"81","author":"Ryu H.W.","year":"2015","unstructured":"Ryu HW, Lee DH, Shin DH, Kim SH, Kwon SH. Aceroside VIII is a new natural selective HDAC6 inhibitor that synergistically enhances the anticancer activity of HDAC inhibitor in HT29 cells.","journal-title":"Planta Med"},{"key":"ref=158","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1016\/j.bmcl.2006.09.002","volume":"16","author":"Jones P.","year":"2006","unstructured":"Jones P, Altamura S, Chakravarty PK, Cecchetti O, De Francesco R, Gallinari P, Ingenito R, Meinke PT, Petrocchi A, Rowley M, Scarpelli R, Serafini S, Steink\u00fchler C. A series of novel, potent, and selective histone deacetylase inhibitors.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=159","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1021\/ja0686256","volume":"129","author":"Maulucci N.","year":"2007","unstructured":"Maulucci N, Chini MG, Micco SD, Izzo I, Cafaro E, Russo A, Gallinari P, Paolini C, Nardi MC, Casapullo A, Riccio R, Bifulco G, Riccardis FD. Molecular insights into azumamide e histone deacetylases inhibitory activity.","journal-title":"J Am Chem Soc"},{"key":"ref=160","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1124\/jpet.102.042903","volume":"304","author":"De Schepper S.","year":"2003","unstructured":"De Schepper S, Bruwiere H, Verhulst T, Steller U, Andries L, Wouters W, Janicot M, Arts J, Van Heusden J. Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin.","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=161","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.7164\/antibiotics.43.1524","volume":"43","author":"Itazaki H.","year":"1990","unstructured":"Itazaki H, Nagashima K, Sugita K, Yoshida H, Kawamura Y, Yasuda Y, Matsumoto K, Ishii K, Uotani N, Nakai H, Terui A, Yoshimatsu S, Ikenishi Y, Nakagawa Y. Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents.","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=162","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1475-2867-12-49","volume":"12","author":"Li L.","year":"2012","unstructured":"Li L, Dai HJ, Ye M, Wang SL, Xiao XJ, Zheng J, Chen HY, Luo YH, Liu J. Lycorine induces cell-cycle arrest in the G0\/G1 phase in K562 cells via HDAC inhibition.","journal-title":"Cancer Cell Int"},{"key":"ref=163","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.bbalip.2012.07.007","volume":"1821","author":"Parolin C.","year":"2012","unstructured":"Parolin C, Calonghi N, Presta E, Boga C, Caruana P, Naldi M, Andrisano V, Masotti L, Sartor G. Mechanism and stereoselectivity of HDAC I inhibition by (R)-9-hydroxystearic acid in colon cancer.","journal-title":"Biochim Biophys Acta"},{"key":"ref=164","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1021\/ol8014623","volume":"10","author":"Ghosh A.K.","year":"2008","unstructured":"Ghosh AK, Kulkarni S. Enantioselective total synthesis of (+)-largazole, A potent inhibitor of histone deacetylase.","journal-title":"Org Lett"},{"key":"ref=165","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/carcin\/bgh123","volume":"25","author":"Druesne N.","year":"2004","unstructured":"Druesne N, Pagniez A, Mayeur C, Thomas M, Cherbuy C, Du\u00e9e PH, Martel P, Chaumontet C. Diallyl disulfide (DADS) increases histone acetylation and p21(waf1\/cip1) expression in human colon tumor cell lines.","journal-title":"Carcinogenesis"},{"key":"ref=166","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1207\/S15327914NC431_11","volume":"43","author":"Lea M.A.","year":"2002","unstructured":"Lea MA, Rasheed M, Randolph VM, Khan F, Shareef A, desBordes C. Induction of histone acetylation and inhibition of growth of mouse erythroleukemia cells by S-allylmercaptocysteine.","journal-title":"Nutr Cancer"},{"key":"ref=167","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1021\/acschembio.7b00330","volume":"12","author":"Porter N.J.","year":"2017","unstructured":"Porter NJ, Christianson DW. Binding of the microbial cyclic tetrapeptide trapoxin A to the class I histone deacetylase HDAC8.","journal-title":"ACS Chem Biol"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/169245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:27:30Z","timestamp":1694564850000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/169245\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,28]]},"references-count":167,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3,28]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026619666190122144949","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3,28]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-10-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}